A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Inclusion Criteria: * Provision of formalin-fixed paraffin embedded tissue sample from primary or metastatic disease * Karnofsky Performance Score of ≥60. * Additional Inclusion Criteria Specific for Arm A and Japan: * Histologically proven diagnosis of GBM. Patients who have had RT for low-grade glioma (LGG) or grade 3 glioma and have subsequently relapsed to histologically confirmed GBM can be considered * A radiological diagnosis of recurrent/relapsed or progressive disease according to RANO criteria. * Completion of first-line radiation at least 6 months prior to Cycle 1 Day 1. * Patients with tumor-induced seizures must be well controlled on a stable anti-epileptic treatment * Willing to receive anti-epileptic prophylaxis for the duration of study drug administration. * Additional Inclusion Criteria Specific for Arm B: \*\*Arm B has now closed to recruitment\*\* * Histologically proven diagnosis of solid tumor malignancy and Magnetic Resonance (MR) imaging documenting brain lesions. * Not eligible for Stereotactic Radiosurgery (SRS) treatment of brain tumor. * Patient has not received any previous brain RT to the area that is to be irradiated. Prior PBRT may be allowed if there is not significant overlap between the prior and new radiation fields. * Non-CNS malignant disease must be sufficiently controlled so that patients can be without additional systemic therapy for the required washout period before starting therapy until 5 days after the end of RT. Req…